SARS-CoV-2 Variant Screening Using a Virus-Receptor-Based Electrical Biosensor

Nano Lett. 2022 Jan 12;22(1):50-57. doi: 10.1021/acs.nanolett.1c03108. Epub 2021 Dec 28.

Abstract

SARS-CoV-2 variants are of particular interest because they can potentially increase the transmissibility and virulence of COVID-19 or reduce the effectiveness of available vaccines. However, screening SARS-CoV-2 variants is a challenge because biosensors target viral components that can mutate. One promising strategy is to screen variants via angiotensin-converting enzyme 2 (ACE2), a virus receptor shared by all known SARS-CoV-2 variants. Here we designed a highly sensitive and portable COVID-19 screening biosensor based on the virus receptor. We chose a dual-gate field-effect transistor to overcome the low sensitivity of virus-receptor-based biosensors. To optimize the biosensor, we introduced a synthetic virus that mimics the important features of SARS-CoV-2 (size, bilayer structure, and composition). The developed biosensor successfully detected SARS-CoV-2 in 20 min and showed sensitivity comparable to that of molecular diagnostic tests (∼165 copies/mL). Our results indicate that a virus-receptor-based biosensor can be an effective strategy for screening infectious diseases to prevent pandemics.

Keywords: ACE2; SARS-CoV-2; biosensor; variant screening; virus receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biosensing Techniques*
  • COVID-19*
  • Humans
  • Receptors, Virus
  • SARS-CoV-2 / isolation & purification*
  • Spike Glycoprotein, Coronavirus

Substances

  • Receptors, Virus
  • Spike Glycoprotein, Coronavirus

Supplementary concepts

  • SARS-CoV-2 variants